Cytosolic Processing Governs TAP-Independent Presentation of a Critical Melanoma Antigen

Area of Science:

• Immunology
• Oncology
• Vaccinology

Background:

• Cancer immunotherapy shows promise but faces challenges with tumor resistance.
• Tumor resistance is frequently linked to defects in the MHC class I antigen presentation pathway.
• Downregulation of TAP and tapasin, crucial for antigen presentation, correlates with poor patient survival in cancers.

Purpose of the Study:

• To investigate the antigen presentation of the PMEL209-217 melanoma vaccine peptide in the context of antigen presentation pathway defects.
• To explore mechanisms underlying the presentation of PMEL209-217, particularly in TAP- and tapasin-deficient cells.
• To identify strategies for enhancing vaccine efficacy by overcoming immune evasion.

Main Methods:

• Assessing the presentation of the PMEL209-217 peptide by various cancer cell lines with defects in the MHC class I antigen presentation pathway (TAP- and/or tapasin-deficient).
• Investigating the role of cytosolic proteasomes and tripeptidyl peptidase 2 (TPP2) in generating and degrading the PMEL209-217 epitope.
• Evaluating the effect of TPP2 inhibition on PMEL209-217 presentation.

Main Results:

• The PMEL209-217 peptide is robustly presented by cell lines deficient in TAP and/or tapasin.
• Cytosolic proteasomes generate the PMEL209-217 peptide, enabling TAP-independent presentation.
• Tripeptidyl peptidase 2 (TPP2) efficiently degrades the PMEL209-217 epitope.
• Inhibition of TPP2 significantly enhances the presentation of PMEL209-217.

Conclusions:

• The PMEL209-217 vaccine candidate demonstrates robustness in presentation, even with defects in the antigen presentation pathway, potentially explaining its efficacy.
• TPP2 plays a critical role in degrading the PMEL209-217 epitope.
• Inhibiting TPP2 represents a promising strategy to improve the therapeutic effectiveness of the PMEL209-217 vaccine by enhancing antigen presentation.